Either through genetic mutational study on FFAR2/3 or their interactive action with targeted agonists and antagonists would help in exploring the exact mechanism of action of FFAR2/3 against various gut hormonal comorbidities such as obesity and T2D. The gene discussed is FFAR2; the disease is obesity due to melanocortin 4 receptor deficiency.